Scienture Stock 5-Day Losing Spree: Stock Falls -70%
Scienture (SCNX) stock hit day 5 of a continuous streak of days with losses, with cumulative losses over this period amounting to a -70% return. The company has lost about $26 Mil in value over the last 5 days, with its current market capitalization at about $11 Mil. The stock remains 87.3% below its value at the end of 2024. This compares with year-to-date returns of 16% for the S&P 500.
SCNX provides novel specialty pharmaceutical products and health services to enhance patient engagement, optimize prescriptions, and address unmet market needs in the U.S.
A single stock can be risky, but there is a huge value to a broader, diversified approach. Strategic asset allocation and diversification help you stay invested. Did you know investors who panicked out of the S&P in 2020 lost significant upside that followed? Trefis High Quality Portfolio and Empirical Asset Management’s asset allocation approach are designed to reduce volatility so you can stay the course.
Comparing SCNX Stock Returns With The S&P 500
The following table summarizes the return for SCNX stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | SCNX | S&P 500 |
|---|---|---|
| 1D | -15.9% | -1.0% |
| 5D (Current Streak) | -70.5% | 1.2% |
| 1M (21D) | -12.1% | 1.7% |
| 3M (63D) | -59.8% | 9.4% |
| YTD 2025 | -87.3% | 16.0% |
| 2024 | 86.9% | 23.3% |
| 2023 | -14.0% | 24.2% |
| 2022 | -82.9% | -19.4% |
What is the point? Sustained weakness can be more than noise. It often signals shifting sentiment or deeper concerns. A multi-day losing streak may warn of further downside, or present an opportunity to buy if fundamentals are intact.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 10 S&P constituents with 3 days or more of consecutive gains and 148 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 5 | 87 |
| 4D | 2 | 24 |
| 5D | 0 | 21 |
| 6D | 3 | 10 |
| 7D or more | 0 | 6 |
| Total >=3 D | 10 | 148 |
Key Financials for Scienture (SCNX)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $1.4 Mil | $0.1 Mil |
| Operating Income | $-4.4 Mil | $-14.7 Mil |
| Net Income | $-17.8 Mil | $9.1 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ1 | 2025 FQ2 |
|---|---|---|
| Revenues | $10,258 | $0 |
| Operating Income | $-3.6 Mil | $-5.2 Mil |
| Net Income | $-3.1 Mil | $-6.7 Mil |
The losing streak SCNX stock is currently on doesn’t inspire much confidence among investors. In contrast, Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.